Evidence map›Paper›PMID 37886596›Full record

ArticleResearch square2023

IL-17 Signaling in Primary Sclerosing Cholangitis Patient-Derived Organoids.

Ana Sofia Garcia Moreno, Maria Eugenia Guicciardi, Alexander Q Wixom, Erik Jessen, Jingchun Yang, Sumera I Ilyas, Jackie K Bianchi, Filippo Pinto E Vairo, Konstantinos N Lazaridis, Gregory J Gores

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ana Sofia Garcia MorenoMayo Clinic, Rochester, MN, USA.
Maria Eugenia GuicciardiMayo Clinic, Rochester, MN, USA.
Alexander Q WixomMayo Clinic, Rochester, MN, USA.
Erik JessenMayo Clinic, Rochester, MN, USA.
Jingchun YangMayo Clinic, Rochester, MN, USA.
Sumera I IlyasMayo Clinic, Rochester, MN, USA.
Jackie K BianchiMayo Clinic, Rochester, MN, USA.
Filippo Pinto E VairoMayo Clinic, Rochester, MN, USA.
Konstantinos N LazaridisMayo Clinic, Rochester, MN, USA.
Gregory J GoresMayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · US

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Nicholas F. LaRusso · 2009 to 2026
$22.2M
Dissecting the pathogenesis and outcomes of PSC using multi-omics by studying the exposome and genomeRC2DK118619 · NIDDK · MAYO CLINIC ROCHESTER · PI LAZARIDIS, KONSTANTINOS N · 2018 to 2022
$7.8M
Cholestatic Liver InjuryR01DK124182 · NIDDK · MAYO CLINIC ROCHESTER · PI GORES, GREGORY J. · 2020 to 2023
$1.4M
NCATS NIH HHS UL1 TR002377NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK124182NIDDK NIH HHS RC2 DK118619
6 · The paper itself

Abstract

The pathogenesis of primary sclerosing cholangitis (PSC) is unclear, although studies implicate IL-17A as an inflammatory mediator in this disease. However, a direct assessment of IL-17 signaling in PSC cholangiocytes is lacking. In this study we aimed to investigate the response of PSC extrahepatic cholangiocyte organoids (ECO) to IL-17A stimulation. Cholangiocytes obtained from PSC and non-PSC patients by endoscopic retrograde cholangiography (ERC) were cultured as ECO. The ECO were treated with vehicle or IL-17A and assessed by transcriptomics, secretome analysis, and genome sequencing (GS). Unsupervised clustering of all integrated scRNA-seq data identified 8 cholangiocyte clusters which did not differ between PSC and non-PSC ECO. However, PSC ECO cells demonstrated a robust response to IL-17 treatment, noted by an increased number of differentially expressed genes (DEG) by transcriptomics, and more abundant chemokine and cytokine expression and secretion. After rigorous filtering, GS identified candidate somatic variants shared among PSC ECO from unrelated individuals. However, no candidate rare variants in genes regulating the IL-17 pathway were identified, but rare variants regulating the MAPK signaling pathway were present in all PSC ECO. In conclusion, PSC and non-PSC patient derived ECO respond differently to IL-17 stimulation implicating this pathway in the pathogenesis of PSC.

Identifiers

PMID37886596
PMCPMC10602181
OpenAlexW4387665854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.